You are here

Positive Phase III Results for Extended-Release Budesonide (Uceris) in Ulcerative Colitis

Drug significantly more effective than placebo in inducing remission (Mar. 18)

Results from a recent phase III study of budesonide (Uceris, Santarus, Inc.) extended-release tablets in patients with ulcerative colitis have been published online in Gut.

In findings from the COlonic RElease Budesonide for the Treatment of Mild to Moderate Ulcerative Colitis II (CORE II) trial, extended-release budesonide 9 mg showed a statistically significant benefit over placebo in inducing combined clinical and endoscopic remission at week 8 (the study’s primary endpoint) among patients with active, mild-to-moderate ulcerative colitis. A total of 410 patients were randomly assigned to treatment with placebo, extended-release budesonide 9 mg, extended-release budesonide 6 mg, or standard budesonide (Entocort EC, AstraZeneca) 9 mg. The percentage of patients achieving the primary endpoint of combined clinical and endoscopic remission at week 8 in the group given extended-release budesonide 9 mg was significantly greater than that observed in the placebo group (17.4% vs. 4.5%, respectively; P = 0.0047).

The FDA approved Uceris (extended-release budesonide) 9 mg for the induction of remission in patients with active, mild-to-moderate ulcerative colitis on January 14, 2013. The drug is taken once daily in the morning with or without food for up to 8 weeks.

Ulcerative colitis is a form of chronic inflammatory bowel disease (IBD) that produces inflammation and ulcers along the inside of the colon, which can interfere with the colon’s normal function. The disease typically starts to manifest in patients as young adults. Ulcerative colitis is an intermittent disease with periods of exacerbated symptoms, or flares, and periods that are relatively symptom-free. Although the symptoms of ulcerative colitis may resolve without treatment, the disease usually requires medication to go into remission. According to the Crohn's and Colitis Foundation of America, 700,000 people in the U.S. have ulcerative colitis.

Sources: Santarus, Inc.; March 18, 2013; and Gut; February 22, 2013.

Recent Headlines

Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
So far in January, the increases average 5%
Fast-acting insulin aspart may simplify mealtime dosing
Simple change in dosage and route may improve a century-old vaccine
Neurodevelopmental deficits detected in Colombian toddlers